There are no trials at this time that target the gastrin-releasing peptide receptor (GRP-R) or the integrin αVβ3 or αVβ5 receptors, which have also been identified as potential targets for neuroendocrine tumors (5). The gene discussed is GRPR; the disease is neuroendocrine neoplasm.